In a phase 2 trial published in The Lancet , retatrutide produced clinically meaningful improvements in glycemic control and robust reductions in body weight among people with type 2 diabetes
In 2026, semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) is available at prices ranging from about $99 per month to over $1,300 per month depending on the channel
"Like for any other disease, the solution has to be long-term and lifelong, and same thing for the disease of obesity
In some embodiments, otic administration of the formulations or compositions described herein avoids toxicity associated with systemic administration (e.g., hepatotoxicity, cardiotoxicity, gastrointestinal side effects, and renal toxicity) of the active agents
Free of:Gluten, Wheat, Dairy, Soy, Yeast